NeoGenomics names Warren Stone CEO effective Jan. 4, 2027

NEO•2026-10-05

NeoGenomics named President and COO Warren Stone as CEO and a board member, effective Jan. 4, 2027. Board Chair Lynn Tetrault will step down that day and leave the board at the 2027 annual meeting.

1. Leadership transition

Stone, 54, joined NeoGenomics in 2022 and previously held senior roles at Ortho Clinical Diagnostics and MilliporeSigma/Merck KGaA. Independent director Michael Kelly will become lead independent director on Jan. 4, 2027.

NeoGenomics names Warren Stone CEO effective Jan. 4, 2027

1. Leadership transition

Related News

Vaxcyte launches $500 million convertible senior notes offering due 2032

authID prices $1.35 million senior secured convertible debenture offering

CenterPoint Energy EVP, CHRO Lauren Chesley Clark files initial beneficial ownership statement

MACOM SVP, GC and Secretary Ambra R. Roth disposes of 653 common shares for $195,900

Aterian replaces auditor UHY with Haskell & White